Continue reading this on our app for a better experience
Open in App
Sign In
Subscribe
premium
latest
news
views
capital
digital edge
options
videos
edgeinvest
events
Subscribe
Home
Capital
Broker's Calls
PREMIUM
Broker's Calls
iX Biopharma 'warming up' with new outlicensing agreement with Seelos Therapeutics: PhillipCapital
Chloe Lim
Wed, Dec 01, 2021 • 05:03 PM GMT+08
• a year ago
• 3 min read
PhillipCapital analyst Paul Chew maintains “buy” rating on iX Biopharma with an increased target price to 35.5 cents
Follow us on
Facebook
and join our
Telegram
channel for the latest updates.
TAGS
iX Biopharma
Phillip Capital
Related News
Company in the news
iX Biopharma completes first phase of its study for dementia-related agitation drug
by Felicia Tan
•
February 10, 2023
Asset management
PhillipCapital issues first luxury wine-based tokens
by Khairani Afifi Noordin
•
December 27, 2022
Broker's Calls
Broker's Digest: Spotify, NetLink NBN Trust, TDCX, iX Biopharma, StarHub
by The Edge Singapore
•
October 06, 2022
Get the latest news updates in your mailbox
Subscribe
Highlights
Geopolitics
Will the Rising Sun keep rising?
September 21, 2023
Trending Now
OCBC becomes first bank in Singapore to offer cross-border payments for customers through Alipay+
Goh Jin Hian, former CEO of New Silkroutes Group and son of former PM Goh Chok Tong charged with false trading
Thomson Medical has 3 months to restore public float
Proposed rezoning of Marina Square could have 'significant upsides' to NAVs, says DBS
DBS keeps 'buy' call and 18 cents target price on Seatrium
Related News
Company in the news
iX Biopharma completes first phase of its study for dementia-related agitation drug
February 10, 2023
Asset management
PhillipCapital issues first luxury wine-based tokens
December 27, 2022
Broker's Calls
Broker's Digest: Spotify, NetLink NBN Trust, TDCX, iX Biopharma, StarHub
October 06, 2022
Get the latest news updates in your mailbox
Subscribe
×
Loading next article...
Download The Edge Singapore App
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
Subscribe
Products & Services
News
Newsletter
Videos
Options
Edge Invest
Advertising
T&Cs
Sitemap
About Us
Our Company
Contact Us
Editorial Team
Join Us
FAQs
Privacy Policy
Malaysia
© 2022 The Edge Publishing Pte Ltd. All rights reserved.